Table 2.
Components of platelet-rich plasma formulations used in different groups at different time points.
| Injection time | Group | Leukocyte concentration (106/ml) | Platelet concentration (1066/ml) | IL-1β concentration (pg/ml) | TNF-α concentration (pg/ml) | PDGF-AB concentration (ng/ml) | TGF-β1 concentration (ng/ml) |
|---|---|---|---|---|---|---|---|
| 4 weeks postoperatively | L-PRP | 51.24±19.53 | 2184.80±428.19 | 56.03±20.13 | 32.30±7.24 | 46.97±11.70 | 101.83±21.09 |
| L-PRP+CAPE | 58.73±23.48 | 2084.10±396.87 | 47.22±19.11 | 32.70±7.34 | 41.60±18.78 | 106.72±23.53 | |
| P-PRP | 0.10±0.11 | 2056.80±331.68 | 2.12±0.53 | 1.44±0.40 | 37.93±13.85 | 96.97±25.06 | |
| P-PRP+CAPE | 0.12±0.11 | 2036.10±314.06 | 2.54±0.92 | 1.43±0.54 | 41.52±17.35 | 101.55±28.12 | |
| 5 weeks postoperatively | L-PRP | 61.83±17.01 | 2030.00±265.67 | 52.18±22.61 | 30.78±6.04 | 50.01±13.57 | 113.74±16.63 |
| L-PRP+CAPE | 55.28±22.44 | 2032.60±270.18 | 56.09±18.99 | 32.28±7.24 | 43.00±15.85 | 99.27±32.77 | |
| P-PRP | 0.22±0.11 | 2007.30±263.81 | 2.55±1.11 | 1.64±0.56 | 38.59±11.81 | 96.00±29.79 | |
| P-PRP+CAPE | 0.15±0.14 | 1981.50±312.42 | 2.82±0.83 | 1.53±0.50 | 35.98±15.01 | 90.23±35.88 | |
| 6 weeks postoperatively | L-PRP | 56.92±26.83 | 1947.50±297.71 | 54.62±18.57 | 32.93±6.73 | 41.08±12.61 | 97.89±16.56 |
| L-PRP+CAPE | 64.86±24.39 | 1935.30±378.01 | 56.80±15.89 | 31.78±8.75 | 40.58±11.00 | 97.97±29.96 | |
| P-PRP | 0.14±0.10 | 1933.30±240.37 | 2.53±0.92 | 1.50±0.75 | 37.66±13.36 | 96.60±28.38 | |
| P-PRP+CAPE | 0.13±0.13 | 1880.10±284.31 | 2.76±0.83 | 1.35±0.52 | 37.14±14.80 | 88.02±21.17 |
L-PRP – leukocyte- and platelet-rich plasma; P-PRP – pure platelet-rich plasma; CAPE – caffeic acid phenethyl ester; IL-1β – interleukin-1β; TNF-α – tumor necrosis factor-a; PDGF-AB – platelet-derived growth factor AB; TGF-β1 – transforming growth factor-β1.